The pros and cons of discontinuing disease-modifying therapies in multiple sclerosis.
John R. Corboy, MD
Advertisement
Articles by John R. Corboy, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What Salanersen's FDA Breakthrough Designation Means for Spinal Muscular Atrophy
2
Weighing Disease-Modifying Therapy Discontinuation in Older, Stable Patients With MS
3
The Future of Alzheimer Disease Care: Toward Biomarker-Guided Personalized Treatment
4
FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy
5